20 May 2024
20 May 2024
On Clinical Trials Day, we take a look at how sponsors are exploring alternative designs to study cell and gene therapies.
Data shows the industry is turning towards decentralization to study the effects of drugs in older populations, but how can Decentralized Clinical Trials (DCTs) be implemented in a suitable, age-appropriate way?
The trial will evaluate the safety, pharmacokinetics, and efficacy of DF-003 in individuals affected by the ROSAH condition.
Kelly Franchetti discusses the evolving role of patient advocates and the key relationships needed to advance drug development.
Vicore Pharma will initiate the Phase IIb trial by the end of H1 2024.
Using the technology, 39 suitable participants were identified and matched with trials via regional pharmacies in days.
The study will be conducted across multiple sites in the US and is expected to extend to Japan and Europe soon.
ENV-101 was found to be well-tolerated in the trial without any serious adverse events reported.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
GlobalData's latest report provides top line data relating to the clinical trials on HER2- Breast Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. It further offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Give your business an edge with our leading industry insights.
